Nanobiotix (NBTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$13.2M

Revenue (quarter)

$6.3M

Revenue growth (year over year)

−79.79%

Gross profit (trailing twelve months)

$13.2M

Gross margin

100.00%

Net income (trailing twelve months)

−$60.9M

Net income (quarter)

−$39.1M

Net income growth (year over year)

−517.86%

Net margin

−460.35%

Return on equity

—

EPS (trailing twelve months)

−$1.26

Book value per share

−$0.75

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

126.01%

Payout ratio

—

Dividend yield

—

Company profile

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

• Is Nanobiotix (NBTX) profitable?

  No. Nanobiotix reported a net loss of $60.9M over the trailing twelve months.

• How much revenue does Nanobiotix (NBTX) make?

  Nanobiotix generated $13.2M in revenue over the trailing twelve months, down 79.79% year over year.

• How do I buy stock in Nanobiotix (NBTX)?

  NBTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.